This review evaluates whether recent technological advances favor echocardiography or cardiac magnetic resonance imaging for right ventricular assessment in pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Recent advances leave echocardiography versus CMR preference unresolved for RV assessment in PAH; leaves open head-to-head trials.
Pulmonary arterial hypertension (PAH) is a progressive, often lethal condition originating in the pulmonary arteriolar tree. It is typically manifested in stereotypical changes in the right ventricle (RV). RV dysfunction is an important mediator of patient symptoms in PAH, and RV failure is the most common cause of mortality in PAH patients. Because of the physiologic importance of the RV, RV imaging is critical in the initial diagnostic evaluation and serial assessment of PAH patients, and can provide indirect insight into the status of the disease at the level of the pulmonary vasculature. This article will focus on whether technological advances in imaging have shifted the debate toward which modality is optimal both for routine clinical practice and for a possible surrogate endpoint in PAH clinical trials.
No takes yet. Share an insight, caveat, or question.
Raina et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: